18F-FDGPET（PET／CT）肾癌显像特点分析

目的评价。肾占位全身18F—FDGPET（PET／CT）显像的应用价值。方法对78例肾占位的18F—FDGPET（PET／CT）显像特点进行分析。其中影像学检查发现肾实性占位28例；肾癌术后复查41例；既往有肾癌手术史后发现肺内占位病变9例。按5．55MBq／kg体质量注入18F—FDG后50min，使用SEIMENSEcatexactHR＋或GEDiscoveryVCT进行三维模式采集。PET判读：在观察到的肾病灶部位设感兴趣区（ROI），以SUVmax≥2．5为阳性（恶性），SUVmax〈2．5为阴性（良性）。PET／CT判读：PET图像标准同上，结合cT影像及融合图像进行诊断。结果病理证实为肾癌的21例中PET阳性11例；7例良性病变中5例错构瘤及1例囊肿PET显示为阴性；11例肾癌为PET／CT显像，9例阳性；13例转移及术后复发者PET阳性10例。结论18F—FDGPET对肾癌原发灶的诊断价值有限，对转移以及术后局部复发的诊断有较高价值。

Characteristics of 18F-FDG PET for space occupying renal cancer

Objective To evaluate the value of whole body 18F-FDG PET（PET/CT） for space occupying renal cancer. Methods Characteristics of whole-body 18F-FDG PET imaging for 78 patients with space occupying solid renal cancer were analyzed, which showed space occupying solid renal lesions in 28, 41, 9 patients, respectively. Fifty minutes after injection with 18F-FDG PET （5.55MBq/kg）, Ecat exact HR or GE discovery VCT was used to collect the 3-dimensional images. ROI was set at the renal foci observed. SUVmax ≥ 2.5 was judged as positive PET（malignant） and SUVmax〈2.5 was judged as negative PET（benign）.The disease was diagnosed following the CT and fusion images in PET/CT. Results Pathological examination showed renal cancer and positive PET in 21 and 11 patients, respectively. Of the 7 patients with benign lesions, 5 were found to be hamartoma and 1 was found to have cyst which was positive for PET. Of the 11 patients who were found to have renal cancer by 18F-FDG PET/CT, 5 were positive for PET. Of the 13 patients with metastasis or relapse after operation, 10 were positive for PET. Conclusion 18F-FDG PET has a limited value for the diagnosis of primary renal cancer but has a rather high value for the diagnosis of metastasis or relapse of renal cancer after operation.